Douglas Dachille
BridgeBio PharmaAbout Douglas A. Dachille
Douglas A. Dachille, age 60, has served as an independent director of BridgeBio Pharma, Inc. since August 2021. He is currently a member of the Audit Committee (appointed March 2025) and the Nominating & Corporate Governance Committee, and is standing for re‑election as a Class III director through the annual meeting following FY2027. He previously served as EVP and Chief Investment Officer of AIG and CEO of First Principles Capital Management; he holds a bachelor’s degree through a Union University/Albany Medical College program and an MBA in finance from the University of Chicago . The Board has determined he is independent under Nasdaq and SEC rules; the Board met nine times in 2024, with all directors meeting at least 75% attendance .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| American International Group (NYSE: AIG) | EVP & Chief Investment Officer | Sep 2015 – Jun 2021 | Led investment oversight for a global insurer |
| First Principles Capital Management | CEO | Sep 2003 – Sep 2015 (acquired by AIG) | Built and led investment management firm |
| Zurich Capital Markets | President & COO | Prior to 2003 | Managed risk/operations in capital markets |
| JPMorgan Chase | Global Head of Proprietary Trading; Co‑Treasurer | Prior roles | Senior leadership in trading/treasury |
| BridgeBio Pharma | Board observer (prior service) | — | Strategic familiarity with BBIO before directorship |
External Roles
| Organization | Role | Start Date | Notes |
|---|---|---|---|
| Equitable Holdings, Inc. (NYSE: EQH) | Director | Jan 2025 | Public company board service |
| PNC Financial Services Group, Inc. (NYSE: PNC) | Director | Feb 2025 | Public company board service |
Board Governance
- Committee assignments: Audit Committee member (chair: Andrea J. Ellis; Dachille appointed Mar 2025), Nominating & Corporate Governance Committee member (chair: Ali J. Satvat) .
- Independence: Board determined all directors except Kumar, Homcy, McCormick are independent (Dachille is independent) .
- Attendance and engagement: Board held 9 meetings in 2024; all directors met ≥75% attendance; Audit Committee held 6 meetings; Nominating & Corporate Governance held 2 meetings .
- Board leadership: Lead Director (non‑independent) Charles Homcy, M.D.; Lead Independent Director Fred Hassan (appointed April 2025) .
- Annual meeting presence: Nine directors attended the 2024 annual meeting .
Fixed Compensation
| Director Compensation (2024) | Amount ($) |
|---|---|
| Annual cash retainer | 50,000 |
| Option awards (grant‑date fair value) | 549,998 |
| Total | 599,998 |
Director compensation policy (in effect through Dec 31, 2025):
- Annual Board cash retainer: $50,000; no additional committee/meeting fees .
- Initial option grant upon election: $1,200,000 value; 10‑year term; strikes at grant‑date close; vests in 3 equal annual installments over 3 years; vesting ceases upon departure unless Board decides otherwise; full acceleration upon a “sale event” per 2021 Plan .
- Annual option grant: $550,000 value; same vesting/term; full acceleration on “sale event” .
- Annual caps: first‑year total comp ≤$1,250,000; subsequent years ≤$600,000; Dachille’s 2024 total ($599,998) is at the cap .
Performance Compensation
| Performance Metric in Director Pay | Disclosure |
|---|---|
| Performance‑based components | None disclosed; director equity grants are time‑based options with 3‑year vesting; no PSU/metric linkage for directors |
Other Directorships & Interlocks
| Entity | Type | Relationship to BBIO |
|---|---|---|
| Equitable Holdings (EQH) | Public company | External board; no BBIO transactions disclosed |
| PNC Financial Services (PNC) | Public company | External board; no BBIO transactions disclosed |
| KKR Genetic Disorder L.P. | >5% BBIO shareholder (10.15%) | Board has KKR affiliate director (Ali Satvat); Dachille not affiliated with KKR |
Potential conflicts: No related‑party transactions disclosed involving Dachille; consulting/related payments disclosed for other directors (Homcy, Lo/QLS, McCormick) but not Dachille .
Expertise & Qualifications
- Decades of investment management, trading, and risk/treasury leadership (AIG CIO; JPMorgan proprietary trading) .
- Financial acumen valuable for Audit/Nominating roles; prior BBIO board observer experience adds continuity .
- Education: MBA in finance (University of Chicago); undergraduate joint program (Union University/Albany Medical College) .
Equity Ownership
| Ownership Detail | Amount | As of | Notes |
|---|---|---|---|
| Shares beneficially owned | 156,983 | Apr 1, 2025 | <1% of outstanding shares |
| Breakdown – Trust shares | 20,000 | Apr 1, 2025 | The Dachille 2012‑1 Family Trust |
| Breakdown – options vested/exercisable ≤60 days | 136,983 | Apr 1, 2025 | Vested/exercisable by May 31, 2025 |
| Outstanding options (total) | 232,305 | Dec 31, 2024 | Aggregate outstanding options |
| Anti‑hedging/pledging policy | Prohibits hedging and pledging | Policy effective Oct 2, 2023 | Insider trading policy applies to directors |
Governance Assessment
-
Strengths:
- Independence and dual committee service (Audit; Nominating & Governance) bolster board effectiveness; appointment to Audit in Mar 2025 adds fresh financial oversight .
- Ownership alignment through option‑heavy director pay; 2024 compensation within policy cap; vesting over 3 years encourages continuity .
- No Dachille‑specific related‑party transactions; company prohibits hedging/pledging; maintains clawback policy (exec‑focused) .
-
Watch items / potential risks:
- Director equity fully accelerates on “sale event,” which can create perceived incentives favoring transactions; mitigated by time‑based vesting and broader governance .
- External financial‑services board roles (EQH, PNC) require ongoing monitoring for any BBIO dealings that could introduce related‑party exposure; none disclosed currently .
- Broader board interlocks with significant holders (KKR via Ali Satvat) necessitate sustained independence rigor in committee deliberations; board affirms independence standards .
-
Investor confidence signals:
- Board/committee meeting cadence and 75%+ attendance indicate active oversight .
- 2024 say‑on‑pay support of 93.6% suggests positive shareholder sentiment toward compensation governance overall (NEO program) .